article thumbnail

JPM24: Riding label expansions and launches, AZ plots course toward 'industry-leading growth' by 2030

Fierce Pharma

In AZ's push to reach industry-leading growth by 2030, confidence is key, chief financial officer Aradhana Sarin said at the J.P. With a late-stage pipeline spanning more than 120 clinical trials and a firm grasp of five major disease areas, AstraZeneca appears confident heading into 2024. | Morgan Healthcare Conference.

Leads 273
article thumbnail

AstraZeneca’s Imfinzi regimen misses the mark in setback for ambitious lung cancer 2030 goal

Fierce Pharma

Failure of the Imfinzi-concurrent-chemoradiotherapy regimen deals a blow to AZ’s goal to target more than half of lung cancer patients by 2030. . | One study in AstraZeneca’s elaborate R&D plan for lung cancer has reached a dead end.

Patients 231
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Korean CDMO Lotte Biologics buys land, sets out to build 3 new plants by 2030

Fierce Pharma

With the new real estate, Lotte plans to build out three separate bio plants by 2030. . | Lotte this week unveiled a land purchase agreement with the Incheon Free Economic Zone Authority in Incheon, Korea.

article thumbnail

AstraZeneca sows $400M investment in push to plant 200M trees by 2030

Fierce Pharma

With that new investment, the company is raising its commitment to plant and nurture 200 million trees across six continents by 2030—the same year AstraZeneca aims to halve its environmental footprint across its entire value chain.

239
239
article thumbnail

Sanofi outlines five-pronged approach to reel in €10B in vaccine sales by 2030

Fierce Pharma

By 2030, Sanofi figures its immunizations could generate more than €10 billion in annual sales, the company said during a vaccines R&D event Thursday. While Dupixent often steals the show, Sanofi isn’t sleeping on its vaccine franchise. |

Sales 226
article thumbnail

AstraZeneca met CEO Pascal Soriot's $40B revenue goal early. Now, it plans 15 drug launches by 2030

Fierce Pharma

Now, it plans 15 drug launches by 2030 aliu Thu, 02/09/2023 - 10:00 AstraZeneca met CEO Pascal Soriot's $40B revenue goal early.

245
245
article thumbnail

With Novo Nordisk, Eli Lilly and AstraZeneca leading the way, Big Pharma's sales will grow 4% annually through 2030: analysts

Fierce Pharma

With Novo Nordisk, Eli Lilly and AstraZeneca leading the way, Big Pharma's sales will grow 4% annually through 2030: analysts kdunleavy Mon, 10/02/2023 - 15:19

Leads 161